Back to top
more

Heron Therapeutics (HRTX)

(Delayed Data from NSDQ)

$2.65 USD

2.65
2,169,424

-0.15 (-5.36%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $2.66 +0.01 (0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).

Heron Therapeutics (HRTX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%

by Zacks Equity Research

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 7.35% and 18.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -36.96% and 2.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Company News For Jan 2, 2019

by Zacks Equity Research

Companies In The News Are: BA,TXT,HRTX,GOOS,CWH

Heron Gains on Priority Review Designation for Pain Drug

by Zacks Equity Research

Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.

Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -4.26% and 6.31%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Heron Therapeutics (HRTX) Q3 Earnings Preview: What to Expect

by Zacks Equity Research

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

    Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 21.74% and 23.30%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

      Heron's Pain Candidate Meets Endpoint in Pivotal Studies

      by Zacks Equity Research

      Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.

        Options Traders Expect Huge Moves in Heron Therapeutics (HRTX) Stock

        by Zacks Equity Research

        Investors in Heron Therapeutics (HRTX) need to pay close attention to the stock based on moves in the options market lately.

          Should You Buy Heron Therapeutics (HRTX) Ahead of Earnings

          by Zacks Equity Research

          Heron Therapeutics (HRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.